LVIS Corporation Unveils Cloud-Based Platform for EEG Diagnostics

LVIS Corporation has launched NeuroMatch Access, a cloud-based SaaS platform designed to streamline EEG diagnostics review and enhance physician collaboration. Now available in the United States, the platform helps improve clinical workflows to enable neurologists to quickly review and interpret EEG data while collaborating in real-time to provide more accurate and timely diagnosis.

At the heart of this innovation is NeuroMatch, a cutting-edge technology that leverages artificial intelligence (AI) to review and interpret EEG signals by removing unwanted artifacts. This technology enables clinicians to visualize and understand the intricate communication pathways of brain circuits, facilitating targeted interventions and restorative strategies to enhance neurological health.

“NeuroMatch represents a transformative step towards democratizing neurological care for patients worldwide,” LVIS Corporation Founder Dr. Jin Hyung Lee, an associate professor at Stanford University, where she leads the Lee Lab focused on brain function restoration. “Our commitment is to harness advanced technology to not only expedite EEG diagnostics but also to make these critical services accessible to all, ensuring that every patient receives the timely and effective care they deserve.”

A first-generation immigrant, Dr. Lee was inspired to study the brain after losing her grandmother to stroke, and she has dedicated more than a decade to developing NeuroMatch, earning numerous awards in the process, including the NIH Directors Pioneer Award (2019), NIH Directors New Innovator Award (2010), NSF CAREER Award (2011),  and the IEEE EMBS BRAIN Grand Challenge Award (2022). Currently, NeuroMatch Access is fully operational for clinical EEG review.

LVIS successfully launched NeuroMatch in South Korea earlier this year, installing the technology in 10 of the country’s top hospitals. The company also launched its first NeuroMatch Center in Daegu, South Korea, to serve as an educational hub. The Center provides monitoring rooms for EEG diagnostics and a lecture hall for training healthcare professionals.

LVIS has secured key regulatory approvals for NeuroMatch, including U.S. Food and Drug Administration clearance in June 2023. Available to neurologists, hospitals, and clinics, NeuroMatch Access provides a scalable, cost-effective solution to modernize diagnostic capabilities and enhance patient care.

Headquartered in Palo Alto, Calif., LVIS Corporation considers itself a pioneer in neurotechnology. The company aims to improve patient care through innovative technological solutions. With a team of leading experts in neurology, AI, and bioengineering, LVIS is dedicated to pushing the boundaries of possibilities in neurological diagnostics and treatment.